Skip to main content
Top
Published in: Systematic Reviews 1/2016

Open Access 01-12-2016 | Research

The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review

Authors: Ferrán Catalá-López, Manuel Ridao, Adolfo Alonso-Arroyo, Anna García-Altés, Chris Cameron, Diana González-Bermejo, Rafael Aleixandre-Benavent, Enrique Bernal-Delgado, Salvador Peiró, Rafael Tabarés-Seisdedos, Brian Hutton

Published in: Systematic Reviews | Issue 1/2016

Login to get access

Abstract

Background

Cost-effectiveness analysis has been recognized as an important tool to determine the efficiency of healthcare interventions and services. There is a need for evaluating the reporting of methods and results of cost-effectiveness analyses and establishing their validity. We describe and examine reporting characteristics of methods and results of cost-effectiveness analyses conducted in Spain during more than two decades.

Methods

A methodological systematic review was conducted with the information obtained through an updated literature review in PubMed and complementary databases (e.g. Scopus, ISI Web of Science, National Health Service Economic Evaluation Database (NHS EED) and Health Technology Assessment (HTA) databases from Centre for Reviews and Dissemination (CRD), Índice Médico Español (IME) Índice Bibliográfico Español en Ciencias de la Salud (IBECS)). We identified cost-effectiveness analyses conducted in Spain that used quality-adjusted life years (QALYs) as outcome measures (period 1989–December 2014). Two reviewers independently extracted the data from each paper. The data were analysed descriptively.

Results

In total, 223 studies were included. Very few studies (10; 4.5 %) reported working from a protocol. Most studies (200; 89.7 %) were simulation models and included a median of 1000 patients. Only 105 (47.1 %) studies presented an adequate description of the characteristics of the target population. Most study interventions were categorized as therapeutic (189; 84.8 %) and nearly half (111; 49.8 %) considered an active alternative as the comparator. Effectiveness of data was derived from a single study in 87 (39.0 %) reports, and only few (40; 17.9 %) used evidence synthesis-based estimates. Few studies (42; 18.8 %) reported a full description of methods for QALY calculation. The majority of the studies (147; 65.9 %) reported that the study intervention produced “more costs and more QALYs” than the comparator. Most studies (200; 89.7 %) reported favourable conclusions. Main funding source was the private for-profit sector (135; 60.5 %). Conflicts of interest were not disclosed in 88 (39.5 %) studies.

Conclusions

This methodological review reflects that reporting of several important aspects of methods and results are frequently missing in published cost-effectiveness analyses. Without full and transparent reporting of how studies were designed and conducted, it is difficult to assess the validity of study findings and conclusions.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Drummond MF. A reappraisal of economic evaluation of pharmaceuticals. Science or marketing? Pharmacoeconomics. 1998;14:1–9.PubMedCrossRef Drummond MF. A reappraisal of economic evaluation of pharmaceuticals. Science or marketing? Pharmacoeconomics. 1998;14:1–9.PubMedCrossRef
3.
go back to reference Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA. 2000;283:2158–60.PubMedCrossRef Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA. 2000;283:2158–60.PubMedCrossRef
5.
go back to reference Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet. 2005;365:1159–62.PubMedCrossRef Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet. 2005;365:1159–62.PubMedCrossRef
6.
go back to reference Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ. 2010;340:c723.PubMedPubMedCentralCrossRef Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ. 2010;340:c723.PubMedPubMedCentralCrossRef
7.
8.
go back to reference Hutton B, Salanti G, Chaimani A, Caldwell DM, Schmid C, Thorlund K, et al. The quality of reporting methods and results in network meta-analyses: an overview of reviews and suggestions for improvement. PLoS One. 2014;9:e92508.PubMedPubMedCentralCrossRef Hutton B, Salanti G, Chaimani A, Caldwell DM, Schmid C, Thorlund K, et al. The quality of reporting methods and results in network meta-analyses: an overview of reviews and suggestions for improvement. PLoS One. 2014;9:e92508.PubMedPubMedCentralCrossRef
9.
go back to reference Elixhauser A, Luce BR, Taylor WR, Reblando J. Health care CBA/CEA: an update on the growth and composition of the literature. Med Care. 1993;31:JS1–JS11. JS18-149.PubMedCrossRef Elixhauser A, Luce BR, Taylor WR, Reblando J. Health care CBA/CEA: an update on the growth and composition of the literature. Med Care. 1993;31:JS1–JS11. JS18-149.PubMedCrossRef
10.
go back to reference Elixhauser A, Halpern M, Schmier J, Luce BR. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care. 1998;36:MS1–9. MS18-147.PubMedCrossRef Elixhauser A, Halpern M, Schmier J, Luce BR. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care. 1998;36:MS1–9. MS18-147.PubMedCrossRef
11.
go back to reference Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976–1997. Ann Intern Med. 2000;132:964–72.PubMedCrossRef Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976–1997. Ann Intern Med. 2000;132:964–72.PubMedCrossRef
12.
go back to reference Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature, 1976–2001. Value Health. 2005;8:3–9.PubMedCrossRef Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature, 1976–2001. Value Health. 2005;8:3–9.PubMedCrossRef
13.
go back to reference Rosen AB, Greenberg D, Stone PW, Olchanski NV, Neumann PJ. Quality of abstracts of papers reporting original cost-effectiveness analyses. Med Decis Making. 2005;25:424–8.PubMedCrossRef Rosen AB, Greenberg D, Stone PW, Olchanski NV, Neumann PJ. Quality of abstracts of papers reporting original cost-effectiveness analyses. Med Decis Making. 2005;25:424–8.PubMedCrossRef
14.
go back to reference Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics. 2009;27:861–72.PubMedCrossRef Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics. 2009;27:861–72.PubMedCrossRef
15.
go back to reference Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA. 2002;287:2809–12.PubMedCrossRef Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA. 2002;287:2809–12.PubMedCrossRef
16.
go back to reference Hutter MF, Rodríguez-Ibeas R, Antonanzas F. Methodological reviews of economic evaluations in health care: what do they target? Eur J Health Econ. 2014;15:829–40.PubMedCrossRef Hutter MF, Rodríguez-Ibeas R, Antonanzas F. Methodological reviews of economic evaluations in health care: what do they target? Eur J Health Econ. 2014;15:829–40.PubMedCrossRef
17.
go back to reference García-Altés A. Twenty years of health care economic analysis in Spain: are we doing well? Health Econ. 2001;10:715–29.PubMedCrossRef García-Altés A. Twenty years of health care economic analysis in Spain: are we doing well? Health Econ. 2001;10:715–29.PubMedCrossRef
18.
go back to reference Oliva J, Del Llano J, Sacristán JA. Analysis of economic evaluations of health technologies performed in Spain between 1990 and 2000. Gac Sanit. 2002;16 Suppl 2:2–11. Oliva J, Del Llano J, Sacristán JA. Analysis of economic evaluations of health technologies performed in Spain between 1990 and 2000. Gac Sanit. 2002;16 Suppl 2:2–11.
19.
go back to reference Rodriguez JM, Paz S, Lizan L, Gonzalez P. The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990–2009 literature. Value Health. 2011;14:458–64.PubMedCrossRef Rodriguez JM, Paz S, Lizan L, Gonzalez P. The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990–2009 literature. Value Health. 2011;14:458–64.PubMedCrossRef
20.
go back to reference Rodríguez Barrios JM, Pérez Alcántara F, Crespo Palomo C, González García P, Antón De Las Heras E, Brosa Riestra M. The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. Eur J Health Econ. 2012;13:723–40.PubMedCrossRef Rodríguez Barrios JM, Pérez Alcántara F, Crespo Palomo C, González García P, Antón De Las Heras E, Brosa Riestra M. The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. Eur J Health Econ. 2012;13:723–40.PubMedCrossRef
21.
go back to reference Rovira J, Antoñanzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics. 1995;8:245–52.PubMedCrossRef Rovira J, Antoñanzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics. 1995;8:245–52.PubMedCrossRef
22.
go back to reference López-Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11:513–20.PubMedCrossRef López-Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11:513–20.PubMedCrossRef
23.
go back to reference Catalá-López F, Alonso-Arroyo A, Aleixandre-Benavent R, Ridao M, Bolaños M, García-Altés A, et al. Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis. PLoS One. 2012;7:e38012.PubMedPubMedCentralCrossRef Catalá-López F, Alonso-Arroyo A, Aleixandre-Benavent R, Ridao M, Bolaños M, García-Altés A, et al. Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis. PLoS One. 2012;7:e38012.PubMedPubMedCentralCrossRef
24.
go back to reference Catalá-López F, García-Altés A. Economic evaluation of healthcare interventions during more than 25 years in Spain (1983–2008). Rev Esp Salud Publica. 2010;84:353–69.PubMedCrossRef Catalá-López F, García-Altés A. Economic evaluation of healthcare interventions during more than 25 years in Spain (1983–2008). Rev Esp Salud Publica. 2010;84:353–69.PubMedCrossRef
25.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA group preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9. W64.PubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA group preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9. W64.PubMedCrossRef
26.
go back to reference Valderas JM, Mendivil J, Parada A, Losada-Yáñez M, Alonso J. Development of a geographic filter for PubMed to identify studies performed in Spain. Rev Esp Cardiol. 2006;59:1244–51.PubMedCrossRef Valderas JM, Mendivil J, Parada A, Losada-Yáñez M, Alonso J. Development of a geographic filter for PubMed to identify studies performed in Spain. Rev Esp Cardiol. 2006;59:1244–51.PubMedCrossRef
27.
go back to reference Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
28.
go back to reference Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7.PubMedCrossRef Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7.PubMedCrossRef
29.
go back to reference Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. PRISMA-P group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.PubMedPubMedCentralCrossRef Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. PRISMA-P group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.PubMedPubMedCentralCrossRef
30.
go back to reference Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365:82–93.PubMedCrossRef Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365:82–93.PubMedCrossRef
31.
go back to reference Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726–32.PubMedCrossRef Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726–32.PubMedCrossRef
32.
go back to reference Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.PubMedPubMedCentralCrossRef Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.PubMedPubMedCentralCrossRef
33.
go back to reference Briggs A, Sculpher M, Claxton K. Decision modeling for health economics evaluation. Oxford: Oxford University Press; 2006. Briggs A, Sculpher M, Claxton K. Decision modeling for health economics evaluation. Oxford: Oxford University Press; 2006.
34.
go back to reference Dwan K, Altman DG, Clarke M, Gamble C, Higgins JP, Sterne JA, et al. Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials. PLoS Med. 2014;11:e1001666.PubMedPubMedCentralCrossRef Dwan K, Altman DG, Clarke M, Gamble C, Higgins JP, Sterne JA, et al. Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials. PLoS Med. 2014;11:e1001666.PubMedPubMedCentralCrossRef
35.
go back to reference Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ. 2014;349:g6501.PubMedPubMedCentralCrossRef Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ. 2014;349:g6501.PubMedPubMedCentralCrossRef
36.
go back to reference Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ. 2010;340:c365.PubMedCrossRef Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ. 2010;340:c365.PubMedCrossRef
37.
go back to reference Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009;1:MR000006.PubMed Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009;1:MR000006.PubMed
38.
go back to reference Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332:699–703.PubMedPubMedCentralCrossRef Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332:699–703.PubMedPubMedCentralCrossRef
39.
go back to reference von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296.CrossRef von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296.CrossRef
40.
go back to reference Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. CHEERS Task Force. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med. 2013;11:80.PubMedPubMedCentralCrossRef Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. CHEERS Task Force. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med. 2013;11:80.PubMedPubMedCentralCrossRef
42.
go back to reference Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005;8:521–33.PubMedCrossRef Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005;8:521–33.PubMedCrossRef
43.
go back to reference Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health. 2003;6:9–17.PubMedCrossRef Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health. 2003;6:9–17.PubMedCrossRef
44.
go back to reference Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313:275–83.PubMedPubMedCentralCrossRef Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313:275–83.PubMedPubMedCentralCrossRef
45.
go back to reference Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1339–41.PubMedCrossRef Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1339–41.PubMedCrossRef
46.
go back to reference Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology. A report on principles. Ann Intern Med. 1995;123:61–70.CrossRef Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology. A report on principles. Ann Intern Med. 1995;123:61–70.CrossRef
47.
go back to reference Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev. 2012;1:60.PubMed Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev. 2012;1:60.PubMed
48.
go back to reference Panic N, Leoncini E, de Belvis G, Ricciardi W, Boccia S. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One. 2013;8:e83138.PubMedPubMedCentralCrossRef Panic N, Leoncini E, de Belvis G, Ricciardi W, Boccia S. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One. 2013;8:e83138.PubMedPubMedCentralCrossRef
49.
go back to reference Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374:86–9.PubMedCrossRef Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374:86–9.PubMedCrossRef
50.
go back to reference Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet. 2014;383:166–75.PubMedPubMedCentralCrossRef Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet. 2014;383:166–75.PubMedPubMedCentralCrossRef
51.
go back to reference Lim ME, Bowen JM, O’Reilly D, McCarron CE, Blackhouse G, Hopkins R, et al. Impact of the 1997 Canadian guidelines on the conduct of Canadian-based economic evaluations in the published literature. Value Health. 2010;13:328–34.PubMedCrossRef Lim ME, Bowen JM, O’Reilly D, McCarron CE, Blackhouse G, Hopkins R, et al. Impact of the 1997 Canadian guidelines on the conduct of Canadian-based economic evaluations in the published literature. Value Health. 2010;13:328–34.PubMedCrossRef
Metadata
Title
The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review
Authors
Ferrán Catalá-López
Manuel Ridao
Adolfo Alonso-Arroyo
Anna García-Altés
Chris Cameron
Diana González-Bermejo
Rafael Aleixandre-Benavent
Enrique Bernal-Delgado
Salvador Peiró
Rafael Tabarés-Seisdedos
Brian Hutton
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2016
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-015-0181-5

Other articles of this Issue 1/2016

Systematic Reviews 1/2016 Go to the issue